Table of Content

1 INTRODUCTION (Page No. - 29)
    1.1 OBJECTIVES OF THE STUDY 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA 
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
    2.2 MARKET ESTIMATION METHODOLOGY 
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    2.3 MARKET GROWTH RATE PROJECTIONS 
           2.3.1 DATA TRIANGULATION
    2.4 RESEARCH ASSUMPTIONS 
           2.4.1 COVID-19 ASSUMPTIONS
    2.5 RISK ANALYSIS 
3 EXECUTIVE SUMMARY (Page No. - 45)
4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 PLASMA FRACTIONATION MARKET OVERVIEW 
    4.2 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT & COUNTRY (2019) 
    4.3 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
5 MARKET OVERVIEW (Page No. - 52)
    5.1 INTRODUCTION 
           5.1.1 MARKET DYNAMICS
    5.2 MARKET DYNAMICS 
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Growing use of immunoglobulins in various therapeutic areas
                    5.2.1.2 Rapidly growing geriatric population
                    5.2.1.3 Growing prevalence of respiratory diseases and AATD
                    5.2.1.4 New indications for plasma products
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 High costs and limited reimbursements
                    5.2.2.2 Market disruption caused by recombinant alternatives
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Increased risk of communicable diseases
                    5.2.3.2 Rising prevalence of bleeding disorders
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Reduced supply of plasma due to low donor turnout
                    5.2.4.2 Stringent government regulations
    5.3 IMPACT ASSESSMENT OF PLASMA FRACTIONATION MARKET 
    5.4 PRICING ANALYSIS 
    5.5 IMPACT OF COVID-19 ON MARKET DYNAMICS 
           5.5.1 DRIVERS AND OPPORTUNITIES
           5.5.2 RESTRAINTS AND CHALLENGES
           5.5.3 CUMULATIVE GROWTH ANALYSIS
    5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
    5.7 VALUE CHAIN ANALYSIS 
    5.8 SUPPLY CHAIN ANALYSIS 
    5.9 ECOSYSTEM ANALYSIS 
    5.10 PATENT ANALYSIS 
    5.11 KEY CONFERENCES AND EVENTS IN 2022–2023 
    5.12 REGULATORY ANALYSIS 
           5.12.1 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES
           5.12.2 REGULATORY SCENARIO IN DIFFERENT REGIONS/COUNTRIES
    5.13 PORTER’S FIVE FORCES ANALYSIS 
           5.13.1 THREAT FROM NEW ENTRANTS
           5.13.2 THREAT FROM SUBSTITUTES
           5.13.3 BARGAINING POWER OF BUYERS
           5.13.4 BARGAINING POWER OF SUPPLIERS
           5.13.5 DEGREE OF COMPETITION
    5.14 TECHNOLOGY ANALYSIS 
           5.14.1 COHN’S COLD ETHANOL PLASMA FRACTIONATION
           5.14.2 GEL FILTRATION PLASMA FRACTIONATION
           5.14.3 HUMAN PLASMA FRACTIONATION BY POLYETHYLENE GLYCOL
           5.14.4 PLASMA FRACTIONATION BY AMMONIUM SULFATE
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
    5.16 KEY BUYING CRITERIA BY END USERS 
6 PLASMA FRACTIONATION MARKET, BY PRODUCT (Page No. - 82)
    6.1 INTRODUCTION 
    6.2 IMMUNOGLOBULINS 
           6.2.1 INTRAVENOUS IMMUNOGLOBULINS
                    6.2.1.1 IVIg holds the largest share of the immunoglobulins market
           6.2.2 SUBCUTANEOUS IMMUNOGLOBULINS
                    6.2.2.1 Benefits of self-administration and lower incidence of non-serious systemic adverse reactions will drive the growth of the SCIg market
           6.2.3 OTHER IMMUNOGLOBULINS
    6.3 OAGULATION FACTOR CONCENTRATES 
           6.3.1 FACTOR VIII
                    6.3.1.1 Factor VIII holds the largest share of the coagulation factor concentrates market
           6.3.2 FACTOR IX
                    6.3.2.1 Rising number of hemophilic patients to drive the growth of this market
           6.3.3 VON WILLEBRAND FACTOR
                    6.3.3.1 Market growth is primarily driven by the increasing prevalence and diagnosis of Von Willebrand disease and hemophilia
           6.3.4 PROTHROMBIN COMPLEX CONCENTRATES
                    6.3.4.1 Advantages of PCC over fresh frozen plasma will support market growth in this segment
           6.3.5 FIBRINOGEN CONCENTRATES
                    6.3.5.1 Safety profile, accuracy, and speed of administration are the key advantages of fibrinogen concentrates
           6.3.6 FACTOR XIII
                    6.3.6.1 Applications in treating rare bleeding disorders will contribute to the demand for factor XIII
           6.3.7 FACTOR XI
                    6.3.7.1 Growing demand for factor XI to treat bleeding disorders in patients to drive growth
    6.4 ALBUMIN 
           6.4.1 RISING DEMAND FOR ALBUMIN AS AN ANTIOXIDANT TO DRIVE MARKET GROWTH
    6.5 PROTEASE INHIBITORS 
           6.5.1 RISING PREVALENCE OF COPD WILL DRIVE THE DEMAND FOR PROTEASE INHIBITORS
    6.6 OTHER PLASMA PRODUCTS 
7 PLASMA FRACTIONATION MARKET, BY APPLICATION (Page No. - 129)
    7.1 INTRODUCTION 
    7.2 NEUROLOGY 
           7.2.1 RISING PREVALENCE OF MAJOR AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
    7.3 IMMUNOLOGY 
           7.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCY DISORDERS AMONG CHILDREN AND ADULTS WILL DRIVE THE GROWTH OF THIS MARKET
    7.4 HEMATOLOGY 
           7.4.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO DRIVE THE DEMAND FOR COAGULATION FACTOR CONCENTRATES AND IMMUNOGLOBULINS
    7.5 CRITICAL CARE 
           7.5.1 INCREASING OFF-LABEL USE OF ALBUMIN AND RISING USE OF ANTICOAGULANTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS
    7.6 PULMONOLOGY 
           7.6.1 RISING PREVALENCE OF ALPHA-1-ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE THE PLASMA FRACTIONATION MARKET FOR PULMONOLOGY
    7.7 HEMATO-ONCOLOGY 
           7.7.1 RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED PRODUCTS
    7.8 RHEUMATOLOGY 
           7.8.1 INCREASING PREVALENCE OF RHEUMATIC CONDITIONS TO DRIVE THE PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY
    7.9 OTHER APPLICATIONS 
8 PLASMA FRACTIONATION MARKET, BY END USER (Page No. - 157)
    8.1 INTRODUCTION 
    8.2 HOSPITALS & CLINICS 
           8.2.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND GROWING NUMBER OF HOSPITALS & CLINICS—KEY FACTORS DRIVING GROWTH
    8.3 CLINICAL RESEARCH LABORATORIES 
           8.3.1 INCREASING NUMBER OF CLINICAL STUDIES ON NEW THERAPEUTIC INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE MARKET GROWTH
    8.4 ACADEMIC INSTITUTES 
           8.4.1 GROWING DEMAND FOR NEW DRUG MOLECULES TO DRIVE THE DEMAND FOR PLASMA PRODUCTS IN ACADEMIC INSTITUTES
9 PLASMA FRACTIONATION MARKET, BY REGION (Page No. - 167)
    9.1 INTRODUCTION 
    9.2 NORTH AMERICA 
           9.2.1 US
                    9.2.1.1 The US is the largest market for plasma fractionation products
           9.2.2 CANADA
                    9.2.2.1 Canada is one of the world’s highest per capita users of IVIg—a key factor driving market growth
    9.3 EUROPE 
           9.3.1 GERMANY
                    9.3.1.1 Germany has the highest plasma fractionation capacity in Europe
           9.3.2 UK
                    9.3.2.1 Increasing incidence of hemophilia and the growing consumption of coagulation factors to drive market growth in the UK
           9.3.3 FRANCE
                    9.3.3.1 High prevalence of bleeding disorders to drive the market for plasma fractionation in France
           9.3.4 ITALY
                    9.3.4.1 Growth in the country’s geriatric population drives the market for plasma fractionation
           9.3.5 SPAIN
                    9.3.5.1 Growing demand for plasma products for the treatment of chronic diseases in the elderly is the key factor driving market growth
           9.3.6 REST OF EUROPE
    9.4 ASIA PACIFIC 
           9.4.1 CHINA
                    9.4.1.1 Rising incidence of diseases such as liver cancer and hepatitis B to drive market growth in China
           9.4.2 JAPAN
                    9.4.2.1 Rising prevalence of neurological disorders and hematological diseases will support market growth in the country
           9.4.3 AUSTRALIA
                    9.4.3.1 Growing demand for plasma products for the treatment of chronic diseases to drive market growth
           9.4.4 INDIA
                    9.4.4.1 Growing healthcare awareness, availability of better diagnostic tools, and the rising geriatric population to drive market growth
           9.4.5 VIETNAM
                    9.4.5.1 Growing pool of patients suffering from COPD, PID, and bleeding disorders to drive market growth
           9.4.6 INDONESIA
                    9.4.6.1 Growing government initiatives to drive market growth
           9.4.7 MALAYSIA
                    9.4.7.1 Increasing prevalence of bleeding disorders will support the plasma fractionation market in Malaysia
           9.4.8 REST OF ASIA PACIFIC
    9.5 LATIN AMERICA 
           9.5.1 BRAZIL
                    9.5.1.1 Growth of vaccine manufacturing to increase the market growth
           9.5.2 ROLATAM
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 TURKEY
                    9.6.1.1 Turkey dominates the plasma fractionation market in the Middle East & Africa
           9.6.2 SAUDI ARABIA
                    9.6.2.1 Developments in healthcare infrastructure to support market growth
           9.6.3 EGYPT
                    9.6.3.1 Growing research on plasma and plasma derivatives will support market growth
           9.6.4 UAE
                    9.6.4.1 Growing government initiatives for healthcare infrastructure development to drive market growth in the UAE
           9.6.5 REST OF THE MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE (Page No. - 240)
     10.1 OVERVIEW 
     10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
     10.3 MARKET SHARE ANALYSIS 
     10.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 
     10.5 COMPANY EVALUATION QUADRANT 
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
     10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
     10.7 COMPETITIVE BENCHMARKING 
             10.7.1 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
             10.7.2 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
             10.7.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES)
     10.8 COMPETITIVE SCENARIO AND TRENDS 
     10.9 COMPETITIVE BENCHMARKING 
11 COMPANY PROFILES (Page No. - 258)
     11.1 KEY PLAYERS 
             11.1.1 CSL
                        11.1.1.1 Business overview
                        11.1.1.2 Products offered
                        11.1.1.3 Recent developments
                        11.1.1.4 MnM view
                                     11.1.1.4.1 Key strengths
                                     11.1.1.4.2 Strategic choices made
                                     11.1.1.4.3 Weaknesses and competitive threats
             11.1.2 GRIFOLS, S.A.
                        11.1.2.1 Business overview
                        11.1.2.2 Products offered
                        11.1.2.3 Recent developments
                        11.1.2.4 MnM view
                                     11.1.2.4.1 Key strengths
                                     11.1.2.4.2 Strategic choices made
                                     11.1.2.4.3 Weaknesses and competitive threats
             11.1.3 SHIRE (TAKEDA PHARMACEUTICAL COMPANY LIMITED)
                        11.1.3.1 Business overview
                        11.1.3.2 Products offered
                        11.1.3.3 Recent developments
                        11.1.3.4 MnM view
                                     11.1.3.4.1 Key strengths
                                     11.1.3.4.2 Strategic choices made
                                     11.1.3.4.3 Weaknesses and competitive threats
             11.1.4 OCTAPHARMA AG
                        11.1.4.1 Business overview
                        11.1.4.2 Products offered
                        11.1.4.3 Recent developments
                        11.1.4.4 MnM view
                                     11.1.4.4.1 Key strengths
                                     11.1.4.4.2 Strategic choices made
                                     11.1.4.4.3 Weaknesses and competitive threats
             11.1.5 KEDRION S.P.A
                        11.1.5.1 Business overview
                        11.1.5.2 Products offered
                        11.1.5.3 Recent developments
                        11.1.5.4 MnM view
                                     11.1.5.4.1 Key strengths
                                     11.1.5.4.2 Strategic choices made
                                     11.1.5.4.3 Weaknesses and competitive threats
             11.1.6 LFB
                        11.1.6.1 Business overview
                        11.1.6.2 Products offered
                        11.1.6.3 Recent developments
             11.1.7 BIOTEST AG
                        11.1.7.1 Business overview
                        11.1.7.2 Products offered
                        11.1.7.3 Recent developments
             11.1.8 SANQUIN
                        11.1.8.1 Business overview
                        11.1.8.2 Products offered
                        11.1.8.3 Recent developments
             11.1.9 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
                        11.1.9.1 Business overview
                        11.1.9.2 Products offered
                        11.1.9.3 Recent developments
             11.1.10 GC PHARMA
                        11.1.10.1 Business overview
                        11.1.10.2 Products offered
                        11.1.10.3 Recent developments
             11.1.11 BIO PRODUCTS LABORATORY LTD.
                        11.1.11.1 Business overview
                        11.1.11.2 Products offered
                        11.1.11.3 Recent developments
             11.1.12 JAPAN BLOOD PRODUCTS ORGANIZATION
                        11.1.12.1 Business overview
                        11.1.12.2 Products offered
             11.1.13 EMERGENT BIOSOLUTIONS
                        11.1.13.1 Business overview
                        11.1.13.2 Products offered
                        11.1.13.3 Recent developments
             11.1.14 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
                        11.1.14.1 Business overview
                        11.1.14.2 Products offered
                        11.1.14.3 Recent developments
             11.1.15 INTAS PHARMACEUTICALS LTD.
                        11.1.15.1 Business overview
                        11.1.15.2 Products offered
                        11.1.15.3 Recent developments
     11.2 OTHER COMPANIES 
             11.2.1 BHARAT SERUMS AND VACCINES LIMITED
             11.2.2 SK PLASMA
             11.2.3 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.
             11.2.4 KABAFUSION
             11.2.5 CENTURION PHARMA
             11.2.6 ADMA BIOLOGICS, INC.
             11.2.7 PLASMAGEN BIOSCIENCES PVT. LTD.
             11.2.8 VIRCHOW BIOTECH PRIVATE LIMITED
             11.2.9 FUSION HEALTHCARE
             11.2.10 HEMARUS THERAPEUTICS LIMITED
12 APPENDIX (Page No. - 322)
     12.1 DISCUSSION GUIDE 
     12.2 AVAILABLE CUSTOMIZATIONS 
     12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 
LIST OF TABLES (380 TABLES)
TABLE 1 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS
TABLE 2 ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG
TABLE 3 NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION (AS OF 2020–2021)
TABLE 4 NUMBER OF PATIENTS TREATED FOR TOP 15 TARGET CONDITIONS IN THE UK
TABLE 5 GERIATRIC POPULATION, BY REGION, 2000−2050
TABLE 6 NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016 VS. 2018
TABLE 7 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY KEY PLAYER, 2021 (USD)
TABLE 8 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY REGION, 2021 (USD)
TABLE 9 SUPPLY CHAIN ECOSYSTEM
TABLE 10 INDICATIVE LIST OF PATENTS IN THE PLASMA FRACTIONATION MARKET
TABLE 11 PLASMA FRACTIONATION MARKET: LIST OF CONFERENCES AND EVENTS
TABLE 12 PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 13 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 14 IVIG VS. SCIG THERAPY
TABLE 15 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
TABLE 16 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 17 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 22 INTRAVENOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
TABLE 23 PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
TABLE 24 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 25 EUROPE: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 SUBCUTANEOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
TABLE 30 PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 EUROPE: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
TABLE 37 PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 39 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)
TABLE 44 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 46 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 50 FACTOR VIII OFFERED BY KEY MARKET PLAYERS
TABLE 51 PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY REGION, 2020–2027 (USD MILLION)
TABLE 52 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 FACTOR IX OFFERED BY KEY MARKET PLAYERS
TABLE 58 PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY REGION, 2020–2027 (USD MILLION)
TABLE 59 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 60 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS
TABLE 65 PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY REGION, 2020–2027 (USD MILLION)
TABLE 66 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 EUROPE: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY MARKET PLAYERS
TABLE 72 PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)
TABLE 73 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 76 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 77 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 78 FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS
TABLE 79 PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)
TABLE 80 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 81 EUROPE: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 84 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 85 FACTOR XIII OFFERED BY KEY MARKET PLAYERS
TABLE 86 PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY REGION, 2020–2027 (USD MILLION)
TABLE 87 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 88 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 89 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 90 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY REGION, 2020–2027 (USD MILLION)
TABLE 93 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 96 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 97 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 ALBUMIN OFFERED BY KEY MARKET PLAYERS
TABLE 99 PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2020–2027 (USD MILLION)
TABLE 100 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 101 EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 102 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 105 PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS
TABLE 106 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION, 2020–2027 (USD MILLION)
TABLE 107 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 108 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 109 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 110 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 112 PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 113 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 114 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 115 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 116 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 118 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 119 NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND THE PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030
TABLE 120 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN NEUROLOGY
TABLE 121 PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 122 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 123 EUROPE: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 124 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 125 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 126 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 127 LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY
TABLE 128 DIAGNOSIS DISTRIBUTION OF DIFFERENT CATEGORIES OF PRIMARY IMMUNODEFICIENCY DISEASE
TABLE 129 PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION, 2013 VS. 2015
TABLE 130 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY
TABLE 131 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 132 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 133 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 134 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 135 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 137 NUMBER OF HEMOPHILIA PATIENTS (2012–2020)
TABLE 138 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATOLOGY
TABLE 139 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 140 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 141 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 142 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 143 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 144 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 145 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN CRITICAL CARE
TABLE 146 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 147 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 148 EUROPE: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 149 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 150 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 151 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 152 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN PULMONOLOGY
TABLE 153 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 154 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 155 EUROPE: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 156 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 157 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 158 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 159 INCIDENCE OF LEUKEMIA, MULTIPLE MYELOMA, AND HODGKIN’S LYMPHOMA, BY REGION, 2012−2018
TABLE 160 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATO-ONCOLOGY
TABLE 161 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 162 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 163 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 164 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 165 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 166 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 167 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 168 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 169 EUROPE: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 170 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 171 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 172 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 173 PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS
TABLE 174 PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 175 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 176 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 177 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 178 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 179 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 180 PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 181 PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 182 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 183 EUROPE: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 184 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 185 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, 2020–2027 (USD MILLION)
TABLE 186 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 187 PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 188 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 189 EUROPE: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 190 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 191 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, 2020–2027 (USD MILLION)
TABLE 192 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 193 PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 194 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 195 EUROPE: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, 2020–2027 (USD MILLION)
TABLE 196 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 197 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 199 PLASMA FRACTIONATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 200 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 201 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 202 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 203 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 204 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 205 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 206 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 207 US: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 208 US: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 209 US: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 210 US: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 211 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 212 CANADA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 213 CANADA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 214 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 215 CANADA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 216 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 217 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 218 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 219 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 220 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 221 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 222 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 223 GERMANY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 224 GERMANY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 225 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 226 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 227 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 228 UK: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 229 UK: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 230 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 231 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 232 NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012–2020
TABLE 233 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 234 FRANCE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 235 FRANCE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 236 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 237 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 238 PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018, AND 2023-E)
TABLE 239 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 240 ITALY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 241 ITALY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 242 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 243 ITALY: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 244 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 245 SPAIN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 246 SPAIN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 247 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 248 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 249 ROE: NUMBER OF HEMOPHILIA PATIENTS, BY COUNTRY, 2012–2018
TABLE 250 ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 251 ROE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 252 ROE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 253 ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 254 ROE: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 255 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 256 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 257 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 258 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 259 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 260 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 261 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 262 CHINA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 263 CHINA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 264 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 265 CHINA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 266 MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN, 2014 VS. 2018 (IN IU/TOTAL POPULATION)
TABLE 267 PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2020
TABLE 268 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 269 JAPAN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 270 JAPAN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 271 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 272 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 273 TOTAL IG (GRAMS) USED IN AUSTRALIA, 2008/09–2017/18
TABLE 274 AUSTRALIAN GOVERNMENT FUNDING FOR THE SUPPLY OF BLOOD AND BLOOD PRODUCTS, 2008–2018 (USD MILLION)
TABLE 275 AUSTRALIA: BLOOD SECTOR OVERVIEW (2017–2018)
TABLE 276 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 277 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 278 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 280 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 281 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2018
TABLE 282 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 283 INDIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 284 INDIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 285 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 286 INDIA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 287 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 288 VIETNAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 289 VIETNAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 290 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 291 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 292 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 293 INDONESIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 294 INDONESIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 295 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 296 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 297 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 298 MALAYSIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 299 MALAYSIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 300 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 301 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 302 ROAPAC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 303 ROAPAC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 304 ROAPAC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 305 ROAPAC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 306 ROAPAC: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 307 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 308 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 309 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 310 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 311 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 312 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 313 BRAZIL: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 314 BRAZIL: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 315 BRAZIL: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 316 BRAZIL: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 317 BRAZIL: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 318 ROLATAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 319 ROLATAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 320 ROLATAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 321 ROLATAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 322 ROLATAM: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 323 HEMOPHILIA PATIENTS IN THE MIDDLE EAST & AFRICA, BY COUNTRY, 2012–2020
TABLE 324 PER CAPITA CONSUMPTION OF FACTORS IX AND VIII (IU/TOTAL POPULATION) IN SOUTH AFRICA, SAUDI ARABIA, AND IRAQ, 2012–2018
TABLE 325 MEA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 326 MEA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 327 MEA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 328 MEA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 329 MEA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 330 MEA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 331 TURKEY: DEMOGRAPHIC INDICATORS
TABLE 332 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 333 TURKEY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 334 TURKEY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 335 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 336 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 337 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 338 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 339 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 340 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 341 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 342 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 343 EGYPT: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 344 EGYPT: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 345 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 346 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 347 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 348 UAE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 349 UAE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 350 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 351 UAE: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 352 HEMOPHILIA PATIENTS IN THE REST OF MIDDLE EAST & AFRICA, 2012−2018
TABLE 353 ROMEA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 354 ROMEA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 355 ROMEA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 356 ROMEA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 357 ROMEA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 358 PLASMA FRACTIONATION MARKET: DEGREE OF COMPETITION
TABLE 359 PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET (2021)
TABLE 360 REGIONAL REVENUE MIX: PLASMA FRACTIONATION MARKET (2021)
TABLE 361 PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–APRIL 2022
TABLE 362 DEALS, JANUARY 2018–APRIL 2022
TABLE 363 OTHER DEVELOPMENTS, JANUARY 2018–APRIL 2022
TABLE 364 PLASMA FRACTIONATION MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 365 PLASMA FRACTIONATION MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [START-UPS/SMES]
TABLE 366 CSL: BUSINESS OVERVIEW
TABLE 367 GRIFOLS, S.A.: BUSINESS OVERVIEW
TABLE 368 SHIRE: BUSINESS OVERVIEW
TABLE 369 OCTAPHARMA AG: BUSINESS OVERVIEW
TABLE 370 KEDRION S.P.A: BUSINESS OVERVIEW
TABLE 371 LFB: BUSINESS OVERVIEW
TABLE 372 BIOTEST AG: BUSINESS OVERVIEW
TABLE 373 SANQUIN: BUSINESS OVERVIEW
TABLE 374 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: BUSINESS OVERVIEW
TABLE 375 GC PHARMA: BUSINESS OVERVIEW
TABLE 376 BIO PRODUCTS LABORATORY LTD.: BUSINESS OVERVIEW
TABLE 377 JAPAN BLOOD PRODUCTS ORGANIZATION: BUSINESS OVERVIEW
TABLE 378 EMERGENT: BUSINESS OVERVIEW
TABLE 379 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: BUSINESS OVERVIEW
TABLE 380 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
LIST OF FIGURES (46 FIGURES)
FIGURE 1 PLASMA FRACTIONATION MARKET
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARIES BY RESPONDENT, DESIGNATION, AND REGION: PLASMA FRACTIONATION MARKET
FIGURE 4 PLASMA FRACTIONATION MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 7 PLASMA FRACTIONATION MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 8 PLASMA FRACTIONATION MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
FIGURE 9 DATA TRIANGULATION METHODOLOGY
FIGURE 10 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 11 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 PLASMA FRACTIONATION MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET
FIGURE 14 GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS IS THE MAJOR FACTOR DRIVING MARKET GROWTH
FIGURE 15 IMMUNOGLOBULINS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN PLASMA FRACTIONATION MARKET IN 2021
FIGURE 16 GERMANY TO REGISTER THE HIGHEST CAGR IN THE PLASMA FRACTIONATION MARKET DURING THE FORECAST PERIOD
FIGURE 17 PLASMA FRACTIONATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 18 NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE, 2012–2018
FIGURE 19 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE PLASMA FRACTIONATION MARKET
FIGURE 20 REVENUE SHIFT & NEW POCKETS FOR PLASMA FRACTIONATION PRODUCT PROVIDERS
FIGURE 21 PROCEDURE OF PLASMA FRACTIONATION
FIGURE 22 VALUE CHAIN ANALYSIS OF THE PLASMA FRACTIONATION MARKET
FIGURE 23 PLASMA FRACTIONATION MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 24 ECOSYSTEM ANALYSIS: PLASMA FRACTIONATION MARKET
FIGURE 25 PATENT APPLICATIONS FOR THE PLASMA FRACTIONATION MARKET, JANUARY 2012–MARCH 2022
FIGURE 26 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR PLASMA FRACTIONATION PRODUCTS
FIGURE 27 BUYING CRITERIA OF END USERS
FIGURE 28 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
FIGURE 29 APAC: PLASMA FRACTIONATION MARKET SNAPSHOT
FIGURE 30 KEY PLAYER STRATEGIES IN THE PLASMA FRACTIONATION MARKET, 2018–2022
FIGURE 31 PLASMA FRACTIONATION MARKET: MARKET SHARE ANALYSIS, 2021 (TOP 5 PLAYERS)
FIGURE 32 REVENUE SHARE ANALYSIS OF PLAYERS IN THE PLASMA FRACTIONATION MARKET (TOP 5)
FIGURE 33 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION QUADRANT, 2021
FIGURE 34 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021
FIGURE 35 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE PLASMA FRACTIONATION MARKET
FIGURE 36 CSL: COMPANY SNAPSHOT (2021)
FIGURE 37 GRIFOLS, S.A.: COMPANY SNAPSHOT (2021)
FIGURE 38 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021)
FIGURE 39 OCTAPHARMA AG: COMPANY SNAPSHOT (2021)
FIGURE 40 KEDRION S.P.A: COMPANY SNAPSHOT (2020)
FIGURE 41 BIOTEST AG: COMPANY SNAPSHOT (2021)
FIGURE 42 SANQUIN: COMPANY SNAPSHOT (2021)
FIGURE 43 GC PHARMA: COMPANY SNAPSHOT (2020)
FIGURE 44 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2020)
FIGURE 45 EMERGENT: COMPANY SNAPSHOT (2021)
FIGURE 46 INTAS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)